Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

PURPOSE: Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a critical signaling kinase in this pathway. We evaluated ibrutinib (PCI-32765), a small-molecule irreversible inhibitor of BTK, in patients with B-...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: Advani, Ranjana H., Buggy, Joseph J., Sharman, Jeff P., Smith, Sonali M., Boyd, Thomas E., Grant, Barbara, Kolibaba, Kathryn S., Furman, Richard R., Rodriguez, Sara, Chang, Betty Y., Sukbuntherng, Juthamas, Izumi, Raquel, Hamdy, Ahmed, Hedrick, Eric, Fowler, Nathan H.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2013
Schlagworte:
ORIGINAL REPORTS
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5505166/
https://ncbi.nlm.nih.gov/pubmed/23045577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.42.7906
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge